The present invention provides an artificial TRAP-cage comprising a selected number of TRAP rings and encapsulated therein a guest cargo.

In some embodiments, a lipofullerene-saccharide compound and a method of inhibiting and/or ameliorating metastasis of neoplastic cells using said compound is disclosed herein. The lipofullerene-saccharide compound may be used in therapeutically effective doses to inhibit the metastasis of neoplasms in mammals. In some embodiments, the method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation including a lipofullerene-saccharide compound. In some embodiments, the lipofullerene-saccharide compound may be formed by reacting (e.g., coupling) a lipid and a saccharide with a fullerene. In some embodiments, neoplastic cells may include pancreatic cancer cells, prostate cancer cells, lung cancer cells, breast cancer cells, colon cancer cells, and/or brain cancer cells. A significant anti-metastatic effect has been observed on a metastatic nude-mouse model of human pancreatic cancer BxPC-3 cell lines constructed orthotopically as a result of therapeutic treatment with the lipofullerene-saccharide conjugate.

A composition including a plant medium and a poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The composition may include one or more nutrients. The composition may be in a solid form, a fluid form, or a combination thereof. The poly-oxygenated aluminum hydroxide is soluble in a fluid. In one embodiment, the poly-oxygenated metal hydroxide composition may have particles having a diameter of 212 m or less, and which may be homogeneous.

The invention provides novel formulations comprising a stable inclusion complex of tributyrin and a cyclodextrin. In one particular embodiment, the formulation comprises an oven dried inclusion complex of tributyrin and -cyclodextrin that is effective in minimizing or preventing the unpleasant taste and odor of tributyrin, thus making it suitable for oral administration and delivery to the digestive tract and intestines. The invention provides compositions of these inclusion complexes and methods of using them that are advantageous as food, medicinal and other products, where the negative sensory properties of tributyrin can be a liability.

Thermogenic molecules and methods of using these molecules for treating or preventing a condition in a subject selected from the group consisting of visceral fat accumulation (e.g., Crohn's disease associated with visceral fat accumulation), obesity, diabetes, pre-diabetes, hypothermia, and chronic inflammation are disclosed. Also disclosed is a method for promoting glucose uptake in peripheral tissues (e.g., adipocytes and muscles) of a subject, enhancing nerve innervation in a subject, activating PI3 kinase in cell, and inducing leptin secretion by an adipocyte. Also disclosed are inhibitors of thermogenic molecules and methods of using these inhibitors to decrease thermogenesis of adipocytes in a subject. Also disclosed are self-assembled, biocompatible nanostructure non-covalently associated with a therapeutic or diagnostic peptide or peptidomimetic.

Provided herein is a composite metal organic framework encapsulating one or more populations of particles, which particles comprise an outer shell region formed from a surfactant and an inner region comprising one or more of a nanoparticle and/or a plurality of protein molecules. Provided also are methods involving the composite metal organic framework.

The present disclosure relates to nanoparticles, controlled-release dosage forms, and methods for the administration of an immunotherapeutic agent.

A composition including a plant medium and a poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The composition may include one or more nutrients. The composition may be in a solid form, a fluid form, or a combination thereof. The poly-oxygenated aluminum hydroxide is soluble in a fluid. In one embodiment, the poly-oxygenated metal hydroxide composition may have particles having a diameter of 212 m or less, and which may be homogeneous.

Described herein are therapeutic compositions and methods of use, for the delivery of various drug substances, in and around the eye, comprising: a drug substance, noncovalently interacting with one or more complexation agent particulates to form drug substance-complex particulates, admixed within a hydrophobic dispersal medium, that collectively forms a stable multiphasic colloidal suspension, that serves as an extended release drug delivery system for ocular drug delivery. Formulation of the drug substance in the multiphasic colloidal suspension can be administered in and around the eye to produce sustained release of therapeutic levels of drug substance within ocular tissues for one or more months without requiring retreatment.

A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O.sub.2) molecules. The carcinoma cells may comprise lung carcinoma (A549). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid.